---
title: 'Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4
  Phase III Trial'
date: '2024-12-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39637340/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241206175011&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: GemCap is a standard option for patients not eligible for
  mFOLFIRINOX. Exploratory evidence suggests that GemCap may be particularly efficacious
  in R0 patients and also in lymph node-negative ...'
disable_comments: true
---
CONCLUSION: GemCap is a standard option for patients not eligible for mFOLFIRINOX. Exploratory evidence suggests that GemCap may be particularly efficacious in R0 patients and also in lymph node-negative ...